^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Cutaneous melanoma: other recommended regimens…combination targeted therapy and PD-L1 therapy if BRAF V600 activating mutation present...vemurafenib/cobimetinib + atezolizumab
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Melanoma)
New
Excerpt:
TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated:...in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.